Haemonetics (NYSE:HAE) had its price target raised by analysts at JPMorgan Chase & Co. from $62.00 to $74.00. They now have a "neutral" rating on the stock.
Haemonetics (NYSE:HAE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $88.00 price target on the stock.
Haemonetics (NYSE:HAE) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Haemonetics Is Still Undervalued, Even After The Rally [Seeking Alpha]
Haemonetics (NYSE:HAE) had its price target raised by analysts at Barrington Research from $86.00 to $90.00. They now have an "outperform" rating on the stock.